Journal of General Internal Medicine

, Volume 19, Issue 4, pp 302–309

Do physicians tailor their recommendations for breast cancer risk reduction based on patient’s risk?

  • Jennifer S. Haas
  • Celia P. Kaplan
  • Steven E. Gregorich
  • Eliseo J. Pérez-Stable
  • Genevieve Des Jarlais
Original Articles

Abstract

OBJECTIVE: To investigate how physicians tailor their recommendations for breast cancer prevention and risk reduction.

DESIGN: Cross-sectional, mail survey.

PARTICIPANTS: Random sample of primary care physicians in California (N=822).

MEASUREMENTS AND MAIN RESULTS: Six standardized patient scenarios were used to assess how women’s breast cancer risk factors influence physicians’ recommendations for screening mammography, counseling about lifestyle behaviors, genetic testing, the use of tamoxifen, prophylactic surgery, and referral to a breast specialist. Over 90% of physicians endorsed mammography for all of the scenarios. Similarly, approximately 80% of physicians endorsed counseling about lifestyle factors for all of the scenarios. Five-year risk of developing breast cancer and family history were both strongly associated with each of the 6 recommendations. Importantly, however, physicians were more likely to endorse the discussion of genetic testing, the use of tamoxifen, and prophylactic surgery for women with a family history of breast cancer compared with women at a higher risk of developing breast cancer but without a family history. Obstetrician-gynecologists were more likely to endorse most of these practices compared with internists.

CONCLUSIONS: Mammography and counseling about lifestyle behaviors are widely endorsed by physicians for breast cancer prevention and risk reduction. Whereas physicians are generally able to tailor their recommendations for prevention and risk reduction based on risk, they may perhaps underutilize genetic evaluation and newer therapeutic options for primary prevention for women who are at high risk of developing breast cancer but do not have a family history.

Key words

breast cancer prevention risk reduction physician survey 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5–27.PubMedGoogle Scholar
  2. 2.
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:77–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98–101.PubMedGoogle Scholar
  7. 7.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian Tamoxifen Prevention Study. Lancet. 1998;352:93–7.PubMedGoogle Scholar
  8. 8.
    Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl CAncer Inst. 1997;22:27–30.Google Scholar
  9. 9.
    Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish Two-County Trial. The effects of age, histologic type, and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst. 1997;22:43–7.Google Scholar
  10. 10.
    Fletcher SW. Breast cancer screening among women in their forties: an overview of the issues. J Natl Cancer Inst. 1997;22:5–9.Google Scholar
  11. 11.
    Kerlikowske K. Efficacy of screening mammography among women aged 40–49 years and 50–69 years. Comparison of relative and absolute benefit. J Natl Cancer Inst. 1997;22:79–86.Google Scholar
  12. 12.
    Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med. 2003;348:1672–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Mezetti M, La Vecchia C, Decarli A, Boyle P, Talamini R, Franceschi S. Population attributable risk for breast cancer: diet, nutrition and physical exercise. J Natl Cancer Inst. 1998;90:389–93.CrossRefGoogle Scholar
  14. 14.
    Gammon MD, Schoenberg JB, Britton JA, et al. Recreational physical activity and breast cancer risk among women under age 45 years. Am J Epidemiol. 1998;147:273–80.PubMedGoogle Scholar
  15. 15.
    Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997;278:1407–11.PubMedCrossRefGoogle Scholar
  16. 16.
    Smith-Warner S, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women. A pooled analysis of cohort studies. JAMA. 1998;279:535–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Kallioniemi A. Molecular signatures of breast cancer—predicting the future. N Engl J Med. 2002;347:2067–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Lurie N, Margolis KL, Mink PJ, Slater JS. Why do patients of female physicians have higher rate of breast and cervical cancer screening? J Gen Intern Med. 1997;12:34–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Herman CJ, Lengerich EJ, Stood G. Variation in recommendations for breast and cervical cancer screening among primary care physicians in North Carolina. South Med J. 1996;89:583–90.PubMedGoogle Scholar
  21. 21.
    Howe HL, Katterhagen JG. Effects of physician outreach programs on rural-urban differences in breast cancer management. J Rural Health. 1997;13:109–17.PubMedCrossRefGoogle Scholar
  22. 22.
    Nattinger AB, Gottlieb MS, Veum J, Yahnke D, Goodwin JS. Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med. 1992;326:1102–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275:913–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Morrow M, Strom EA, Bassett LW, et al. Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002;52:256–76.PubMedGoogle Scholar
  25. 25.
    Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95:1692–702.PubMedGoogle Scholar
  26. 26.
    Lipsitz SR, Fitzmaurice GM, Orav EJ, Laird NM. Performance of generalized estimating equations in practical situations. Biometrics. 1994;50:270–8.PubMedCrossRefGoogle Scholar
  27. 27.
    U.S. Preventive Services Task Force. 2002. Available at: http://www.ahcpr.gov/clinic/uspstfix.htm. Accessed February 27, 2004.Google Scholar
  28. 28.
    Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995;273:149–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Willet WC, Browne ML, Bain C. Relative weight and risk of breast cancer among premenopausal women. Am J Epidemiol. 1985;122:731–9.Google Scholar
  30. 30.
    Hunter DJ, Willett WC. Nutrition and breast cancer. Cancer Causes Control. 1996;7:56–68.PubMedCrossRefGoogle Scholar
  31. 31.
    Pathak DR, Whittemore AS. Combined effects of body size, parity and menstrual events on breast cancer incidence in seven countries. Am J Epidemiol. 1992;135:153–67.PubMedGoogle Scholar
  32. 32.
    Hankinson SE, Willet WC, Manson JE. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995;87:1297–302.PubMedCrossRefGoogle Scholar
  33. 33.
    Sakorafas GH. The management of women at high risk for the development of breast cancer: risk estimation and preventative strategies. Cancer Treat Rev. 2003;29:79–89.PubMedCrossRefGoogle Scholar
  34. 34.
    Ernster VL, Ballard-Barbash R, Barlow WE, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546–54.PubMedGoogle Scholar
  35. 35.
    Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160:953–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev. 2003;12:295–303.PubMedGoogle Scholar
  37. 37.
    Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet. 2002;360:817–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526–32.PubMedCrossRefGoogle Scholar
  39. 39.
    Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997;336:1465–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Kinney AY, Richards C, Vernon SW, Vogel VG. The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial. Prev Med. 1998;27(5 Part 1):713–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Fox SA, Siu AL, Stein JA. The importance of physician communication on breast cancer screening of older women. Arch Intern Med. 1994;154:2058–68.PubMedCrossRefGoogle Scholar
  42. 42.
    Armstrong K, Stopfer J, Calzone K, Fitzgerald G, Coyne J, Weber B. What does my doctor think? Preferences for knowing the doctor’s opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test. 2002;6:115–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: is there enough time for prevention? Am J Public Health. 2003;93:635–41.PubMedGoogle Scholar
  44. 44.
    Houn F, Helzlsouer KJ, Friedmna NB, Stefanek ME. The practice of prophylactic mastectomy. A survey of Maryland surgeons. Am J Public Health. 1995;85:801–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Frank E, Rock J, Sara D. Characteristics of female obstetrician-gynecologists in the United States. Obstet Gynecol. 1999;94(5 Part 1):659–65.PubMedCrossRefGoogle Scholar
  46. 46.
    Gandhi TK, Francis EC, Puopolo AL, Burstin HR, Haas JS, Brennan TA. Inconsistent report cards: assessing the comparability of various measures of the quality of ambulatory care. Med Care. 2002;40:155–65.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2004

Authors and Affiliations

  • Jennifer S. Haas
    • 1
  • Celia P. Kaplan
    • 2
  • Steven E. Gregorich
    • 2
  • Eliseo J. Pérez-Stable
    • 2
  • Genevieve Des Jarlais
    • 2
  1. 1.the Division of General MedicineBrigham and Women’s HospitalBoston
  2. 2.Medical Effectiveness Research Center, Division of General Internal Medicine, Department of MedicineUniversity of CaliforniaSan Francisco

Personalised recommendations